# Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

> **NCT02971397** · PHASE1 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 40 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **PROCEDURE:** Bone Marrow Aspiration and Biopsy
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02971397
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2018-03
- **Final completion:** 2018-08-08
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02971397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02971397, "Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02971397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*